MiniMed: Next-Generation Diabetes Platform Supports A Buy Rating (NASDAQ:MMED)
· seekingalpha.com
MiniMed's double-digit revenue growth is driven by strong international adoption, expanding CGM, and timely product launches. Learn why MMED stock is a buy.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...